The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome
Authors:
- 24 June 2022
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (2) , 451-460
Abstract
Background Hypogammaglobulinemia is a major adverse effect from rituximab. However, the association between rituximab-induced hypogammaglobulinemia and infection frequency is unknown. Methods Patients who received rituximab for complicated nephrotic syndrome between February 2006 and October 2020 were enrolled in this retrospective observational study. Infections requiring antibacterial or antiviral agents or hospitalization were identified, and the characteristics of infections were compared according to infection type. Results One hundred and forty patients were enrolled. Fifty infection events were detected in 36 patients, 45 infection events in 32 patients required hospitalization, and 1 severe infection event required intensive care unit admission. In eight patients who developed severe hypogammaglobulinemia (serum IgG level < 200 mg/dL) for more than 1 year after rituximab treatment, eight infections occurred in six patients; six of these infections did not occur during the period of severe hypogammaglobulinemia. Febrile neutropenia accounted for 54.2% (13/24) of all infections among the patients with hypogammaglobulinemia. The incidence of infections was 0.028 (95% confidence interval = 0.017–0.448), 0.071 (95% [CI] = 0.041–0.114), and 0.096 (95% [CI] = 0.019–0.282) patient-years in patients with normal serum IgG levels and those with mild and severe hypogammaglobulinemia, respectively. Immunoglobulin replacement therapy was not administered to any patients except for the treatment of infection. Conclusions Our results showed no statistically significant association between hypogammaglobulinemia severity and infection rate. In addition, the frequency of infection was relatively low even in patients with severe hypogammaglobulinemia, suggesting that immunoglobulin replacement therapy may not be necessary for rituximab-treated patients with severe hypogammaglobulinemia. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.Keywords
This publication has 33 references indexed in Scilit:
- Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United StatesThe Journal of Pediatrics, 2013
- Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent InfectionsClinical Lymphoma Myeloma and Leukemia, 2013
- Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndromePediatric Nephrology, 2012
- Occurrence of infection among children with nephrotic syndrome during hospitalizationsNephrology, 2012
- Does rituximab increase the incidence of infectious complications? A narrative reviewInternational Journal of Infectious Diseases, 2011
- Registries in rheumatoid arthritis and autoimmune diseases: data from the French registriesRheumatology, 2010
- Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasisInternational Journal of Hematology, 2010
- The effects of rituximab on immunocompetency in patients with autoimmune diseaseArthritis & Rheumatism, 2007
- Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysisArthritis & Rheumatism, 2007
- Assessment and clinical interpretation of reduced IgG valuesAnnals of Allergy, Asthma & Immunology, 2007